

## No 1: Progress in Sarcoma Management

- 4 Bone Sarcoma ... Turning the Corner  
*Samuel V. Agresta, MD, MPH & TM*
- 7 Practical Issues of Intraoperative Frozen Section Diagnosis of Bone and Soft Tissue Lesions  
*Marilyn M. Bui, MD, PhD, Prudence Smith, MD, Samuel V. Agresta, MD, MPH & TM, David Cheong, MD, and G. Douglas Letson, MD*
- 13 Orthopedic Surgery Options for the Treatment of Primary Osteosarcoma  
*German A. Marulanda, MD, Eric R. Henderson, MD, David A. Johnson, PA-C, G. Douglas Letson, MD, and David Cheong, MD*
- 21 Advanced-Technology Radiation Therapy for Bone Sarcomas  
*Samir Patel, MD, and Thomas F. DeLaney, MD*
- 38 Outpatient Chemotherapy Plus Radiotherapy in Sarcomas: Improving Cancer Control With Radiosensitizing Agents  
*Pete Anderson, MD, PhD, Dolly Aguilera, MD, Margaret Pearson, CNP, and Shaio Woo, MD*
- 47 Therapeutic Potential of Directed Tyrosine Kinase Inhibitor Therapy in Sarcomas  
*Audrey C. Shor, PhD, MPH, Samuel V. Agresta, MD, MPH & TM, Gina Z. D'Amato, MD, and Vernon K. Sondak, MD*
- 55 Current Issues in Adolescent and Young Adult Cancer Survivorship  
*Hatem Soliman, MD, and Samuel V. Agresta, MD, MPH & TM*
- 63 Cultural Values and Secondary Prevention of Breast Cancer in African American Women  
*Ellen Burke Beckjord, PhD, MPH, and Ann C. Klassen, PhD*
- 72 Colorectal Cancer Screening and African Americans: Findings From a Qualitative Study  
*Richard C. Palmer, DrPH, Lynn A. Midgette, MPH, and Irene Dankwa, MD, MPH*
- 80 Transcatheter Arterial Chemoembolization and Percutaneous Ethanol Injection for Hepatocellular Carcinoma: A Retrospective Review of the Veterans Affairs Caribbean Healthcare System  
*Jessica Narvaez-Lugo, MD, William W. Cáceres, MD, FACP, Doris H. Toro, MD, FACP, Manuel R. Pérez-González, MD, Alvin A. Almodovar, MD, Awilda M. Maldonado-Mercado, MD, FACP, Norma Salgado, MD, and Gerant M. Rivera-Santeliz, MD*




## No 2: Personalized Treatment Approaches in Radiation Oncology

- 100 Personalized Treatment Approaches in Radiation Oncology: The Future Is Now  
*Eleanor E. R. Harris, MD, and Craig W. Stevens, MD, PhD*
- 104 Stereotactic Body Radiation Therapy: Transcending the Conventional to Improve Outcomes  
*Thomas J. Dilling, MD, and Sarah E. Hoffe, MD*
- 112 Functional Lung Imaging in Thoracic Cancer Radiotherapy  
*Geoffrey Zhang, PhD, Thomas J. Dilling, MD, Craig W. Stevens, MD, PhD, and Kenneth M. Forster, PhD*

- 120 Cardiac Mortality and Morbidity After Breast Cancer Treatment  
*Eleanor E. R. Harris, MD*
- 130 Molecular Analysis-Based Treatment Strategies for Non-Small Cell Lung Cancer  
*Gerold Bepler, MD, PhD, Mubeena Begum, MBBS, MSPH, and George R. Simon, MD, FACP, FCCP*
- 140 The Use of Blood Biomarkers to Predict Radiation Lung Toxicity: A Potential Strategy to Individualize Thoracic Radiation Therapy  
*Feng-Ming (Spring) Kong, MD, PhD, MPH, Xiaoping Ao, PhD, Li Wang, MD, PhD, and Theodore S. Lawrence, MD, PhD*
- 151 Predicting Response to Clinical Radiotherapy: Past, Present, and Future Directions  
*Javier F. Torres-Roca, MD, and Craig W. Stevens, MD, PhD*
- 157 Barriers and Facilitators for Colorectal Cancer Screening Practices in the Latino Community: Perspectives From Community Leaders  
*Ana Natale-Pereira, MD, MPH, Jonnie Marks, PhD, Marielos Vega, RN, BSN, Dawne Mouzon, MPH, Shawna V. Hudson, PhD, and Debbie Salas-Lopez, MD, MPH*
- 166 Apsáalooke Women's Experiences With Pap Test Screening  
*Adina J. Smith, PhD, Suzanne Christopher, PhD, Victoria R. LaFromboise, MS, Bethany L. Letiecq, PhD, and Alma Knows His Gun McCormick*
- 174 Colorectal Cancer Screening Practices of Primary Care Physicians in Washington State  
*Peggy A. Hannon, PhD, MPH, Diane P. Martin, PhD, Jeffrey R. Harris, MD, MPH, MBA, and Deborah J. Bowen, PhD*

## No 3: Melanoma

- 192 Melanoma: Promising New Discoveries and Treatment Modalities for Difficult Clinical Scenarios  
*Jonathan S. Zager, MD, and Adil I. Daud, MD*
- 196 Activated Stat-3 in Melanoma  
*Jane L. Messina, MD, Hua Yu, PhD, Adam I. Riker, MD, FACS, Pamela N. Munster, MD, Richard L. Jove, PhD, and Adil I. Daud, MD*
- 202 The Impact of Genomics in Understanding Human Melanoma Progression and Metastasis  
*Suping Ren, MD, PhD, Suhu Liu, MD, PhD, Paul Howell, Jr, BS, Yaguang Xi, MD, Steven A. Enkemann, MS, PhD, Jingfang Ju, PhD, and Adam I. Riker, MD, FACS*
- 216 Surgical Management of Melanoma In Situ on Chronically Sun-Damaged Skin  
*Graham S. Clark, MD, Effie C. Pappas-Politis, MD, Basil S. Cherpelis, MD, Jane L. Messina, MD, Mecker G. Möller, MD, C. Wayne Cruse, MD, and L. Frank Glass, MD*
- 225 Therapy for Unresectable Recurrent and In-Transit Extremity Melanoma  
*Mark I. Gimbel, MD, Keith A. Delman, MD, and Jonathan S. Zager, MD*
- 233 Radiation Therapy as Primary and Adjuvant Treatment for Local and Regional Melanoma  
*Lawrence B. Berk, MD, PhD*



- 239 Treatment Options for Limited or Symptomatic Metastatic Melanoma  
*James M. McLoughlin, MD, Jonathan S. Zager, MD, Vernon K. Sondak, MD, and Lawrence B. Berk, MD, PhD*
- 248 Melanoma in Hispanic and Black Americans  
*Panta Rouhani, MPH, Shasa Hu, MD, and Robert S. Kirsner, MD, PhD*
- 254 Establishing a Patient Navigator Program to Reduce Cancer Disparities in the American Indian Communities of Western South Dakota: Initial Observations and Results  
*Daniel G. Petereit, MD, Kevin Molloy, RN, Mary L. Reiner, BA, CCRP, Petra Helbig, Dipl-Psych, Kristin Cina, BS, Raylene Miner, Caroline Spotted Tail, Catherine Rost, Patricia Conroy, and Chester R. Roberts, PhD*
- 260 Establishing Trusting Partnerships for Successful Recruitment of American Indians to Clinical Trials  
*Daniel G. Petereit, MD, and Linda Burhansstipanov, MSPH, DrPH, CHES*

- 322 Interdisciplinary Management of an Intraductal Papillary Mucinous Neoplasm of the Pancreas  
*Rajesh M. Nair, MD, James S. Barthel, MD, Barbara A. Centeno, MD, Junsung Choi, MD, Jason B. Klapman, MD, and Mokenge P. Malafa, MD*
- 334 Willingness to Participate in Cancer Screenings: Blacks vs Whites vs Puerto Rican Hispanics  
*Ralph V. Katz, DMD, MPH, PhD, Cristina Claudio, PhD, Nancy R. Kressin, PhD, B. Lee Green, PhD, Min Qi Wang, PhD, and Stefanie Luise Russell, DDS, MPH, PhD*
- 344 Participation in Biomedical Research Studies and Cancer Screenings: Perceptions of Risks to Minorities Compared With Whites  
*Ralph V. Katz, DMD, MPH, PhD, Min Qi Wang, PhD, B. Lee Green, PhD, Nancy R. Kressin, PhD, Cristina Claudio, PhD, Stefanie Luise Russell, DDS, MPH, PhD, and Christelle Sommerville, MPH, MS, CCRP*
- 352 Management of Nerve Sheath Tumors Arising in the Sympathetic Chain  
*Surbhi Jain, MD, Kristin Houseknecht, MPH, Aryn M. Rojiani, MD, PhD, Matthias Setzer, MD, and Frank D. Vrionis, MD, MPH, PhD*

## No 4: Pancreatic Cancer

- 276 New Insights and Gains in Pancreatic Cancer  
*Mokenge P. Malafa, MD*
- 280 Early Detection of Pancreatic Cancer: Why, Who, and How to Screen  
*Jason Klapman, MD, and Mokenge P. Malafa, MD*
- 288 Outcomes Following Resection of Pancreatic Adenocarcinoma: 20-Year Experience at a Single Institution  
*James F. Helm, MD, PhD, Barbara A. Centeno, MD, Domenico Coppola, MD, Mihaela Druta, MD, Jong Y. Park, PhD, Dung-Tsa Chen, PhD, Pamela J. Hodul, MD, Larry K. Kvols, MD, Timothy J. Yeatman, MD, Larry C. Carey, MD, Richard C. Karl, MD, and Mokenge P. Malafa, MD*
- 295 Borderline Resectable Pancreatic Cancer: On the Edge of Survival  
*Gregory M. Springett, MD, PhD, and Sarah E. Hoffe, MD*
- 308 Cancer of the Pancreas: Are We Making Progress? A Review of Studies in the US Oncology Research Network  
*Thomas Cartwright, MD, Donald A. Richards, MD, PhD, and Kristi A. Boehm, MS*
- 314 Aggressive Surgical Resection in the Management of Pancreatic Neuroendocrine Tumors: When Is It Indicated?  
*Pamela J. Hodul, MD, Jonathan R. Strosberg, MD, and Larry K. Kvols, MD*

## No. 4 Supplement 2008: Myelodysplastic Syndromes: Present Status and New Avenues to Optimize Clinical Outcome

- 2 Challenges in Myelodysplastic Syndromes: Raising Awareness and Promoting New Insight in Therapeutic Options  
*Alan F. List, MD*
- 4 Myelodysplastic Syndromes: Diagnosis and Staging  
*Luca Malcovati, MD, and Stephen D. Nimer, MD*
- 14 Changing the Treatment Paradigm in Myelodysplastic Syndromes  
*Ghulam Mufti, MB, DM, FRCP, FRCPath, and Tara L. Chen, PharmD*
- 29 Treatment Strategies to Optimize Clinical Benefit in the Patient With Myelodysplastic Syndromes  
*Alan F. List, MD*
- 40 Future Directions in Myelodysplastic Syndrome: Newer Agents and the Role of Combination Approaches  
*Steven D. Gore, MD, and Evelyn R. Hermes-DeSantis, PharmD, BCPS*